Richard Douglas
CIK: 0001021015
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Jun 20, 2026NVAX
NOVAVAX INC
Exercise(M)Direct18.9K shares- - Jun 18, 2026NVAX
NOVAVAX INC
Award(A)DirectRestricted Stock Units
14.2K shares- - Jun 18, 2026NVAX
NOVAVAX INC
Award(A)DirectStock Option (Right to Buy)
21.3K shares- - Jun 17, 2026MXCT
MAXCYTE, INC.
Award(A)Direct30.4K shares- - Jun 9, 2026ALDX
Aldeyra Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
19.9K shares- - Jun 9, 2026ALDX
Aldeyra Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
70K shares- - Jun 9, 2026ALDX
Aldeyra Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
2.3K shares- - Mar 19, 2026ALDX
Aldeyra Therapeutics, Inc.
Purchase(P)Direct70K shares at avg. $1.40$98K - Aug 13, 2025MXCT
MAXCYTE, INC.
Purchase(P)Direct80K shares at avg. $1.39$111K - Jun 20, 2025NVAX
NOVAVAX INC
Award(A)DirectRestricted Stock Units
18.9K shares- - Jun 20, 2025NVAX
NOVAVAX INC
Award(A)DirectStock Option (Right to Buy)
28.3K shares at avg. $6.42- - Jun 18, 2025MXCT
MAXCYTE, INC.
Award(A)Direct29.2K shares- - Jun 12, 2025NVAX
NOVAVAX INC
Exercise(M)Direct10.4K shares- - Jun 10, 2025ALDX
Aldeyra Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
62.7K shares- - Jun 10, 2025ALDX
Aldeyra Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
14.5K shares- - Jun 10, 2025ALDX
Aldeyra Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
1.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 20, 2026 |  NVAX NOVAVAX INC | Exercise(M) | 18,880 | - | $0 | Direct |
| Jun 18, 2026 | NVAX NOVAVAX INC | Award(A) Restricted Stock Units | 14,180 | - | - | Direct |
| Jun 18, 2026 | NVAX NOVAVAX INC | Award(A) Stock Option (Right to Buy) | 21,270 | - | - | Direct |
| Jun 17, 2026 |  MXCT MAXCYTE, INC. | Award(A) | 30,421 | - | $0 | Direct |
| Jun 9, 2026 |  ALDX Aldeyra Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 19,909 | - | - | Direct |
| Jun 9, 2026 | ALDX Aldeyra Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 70,000 | - | - | Direct |
| Jun 9, 2026 | ALDX Aldeyra Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 2,323 | - | - | Direct |
| Mar 19, 2026 | ALDX Aldeyra Therapeutics, Inc. | Purchase(P) | 70,000 | $1.40 | $98,000 | Direct |
| Aug 13, 2025 | MXCT MAXCYTE, INC. | Purchase(P) | 80,000 | $1.39 | $111,040 | Direct |
| Jun 20, 2025 | NVAX NOVAVAX INC | Award(A) Restricted Stock Units | 18,884 | - | - | Direct |
| Jun 20, 2025 | NVAX NOVAVAX INC | Award(A) Stock Option (Right to Buy) | 28,326 | $6.42 | - | Direct |
| Jun 18, 2025 | MXCT MAXCYTE, INC. | Award(A) | 29,210 | - | - | Direct |
| Jun 12, 2025 | NVAX NOVAVAX INC | Exercise(M) | 10,420 | - | - | Direct |
| Jun 10, 2025 | ALDX Aldeyra Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 62,728 | - | - | Direct |
| Jun 10, 2025 | ALDX Aldeyra Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 14,476 | - | - | Direct |
| Jun 10, 2025 | ALDX Aldeyra Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 1,689 | - | - | Direct |
1-16 of 16 transactions
About DOUGLAS RICHARD
DOUGLAS RICHARD (SEC CIK 0001021015) files insider reports with the SEC as Director of NOVAVAX INC (NVAX), Director of MAXCYTE, INC. (MXCT) and Director of Aldeyra Therapeutics, Inc. (ALDX).
Signal8 holds 9 ownership filings by DOUGLAS RICHARD, all Form 4s, filed between Jun 12, 2025 and Jun 23, 2026. Those filings report 16 transactions, from Jun 10, 2025 to Jun 20, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on DOUGLAS RICHARD's filings is in LEXINGTON, MA.
Recent filings by DOUGLAS RICHARD
- Jun 20, 2026: Option exercise of NVAX shares (Form 4, code M).
- Jun 18, 2026: Grants or awards of NVAX derivative securities (2 lines, Form 4, code A).
- Jun 17, 2026: Grant or award of MXCT shares (Form 4, code A).
- Jun 9, 2026: Grants or awards of ALDX derivative securities (3 lines, Form 4, code A).
- Mar 19, 2026: Open-market purchase of ALDX shares (Form 4, code P).
Other insiders filing for NOVAVAX INC (NVAX)
- Rodgers Richard J, Director
- King Rachel K., Director
- MCGLYNN MARGARET G, Director
- MOTT DAVID M, Director
- Alton Gregg H, Director
- Shiver John W., Director